^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Marginal Zone Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    01/06/2020
    Excerpt:
    Table 6: Summary of recommendations: EMZL- Other treatments including ChT, immunotherapy or combination chemoimmunotherapy are indicated in patients with symptomatic disseminated disease, contraindications to RT, failure after antibiotics or after local therapy or clinical suspicion of histological transformation:...rituximab monotherapy [III, B]...for (clinically suspected or biopsy-proven) histological transformation....Rituximab alone is the preferred initial therapy in patients with SMZL [III, A].
    DOI:
    10.1016/j.annonc.2019.10.010
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    01/06/2020
    Excerpt:
    Table 6: Summary of recommendations: EMZL- Other treatments including ChT, immunotherapy or combination chemoimmunotherapy are indicated in patients with symptomatic disseminated disease, contraindications to RT, failure after antibiotics or after local therapy or clinical suspicion of histological transformation: R-chlorambucil [I, A], R-bendamustine [III, A], rituximab monotherapy [III, B], R-lenalidomide [III, C] and R-CHOP for (clinically suspected or biopsy-proven) histological transformation.
    Secondary therapy:
    chlorambucil; bendamustine
    DOI:
    10.1016/j.annonc.2019.10.010
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Marginal Zone Lymphomas...Preferred regimens...Rituximab
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Marginal Zone Lymphoma: First-line therapy for elderly or infirm…Other recommended regimens…Cyclophosphamide ± rituximab…Lenalidomide + rituximab...Chlorambucil ± rituximab...Preferred Regimens…Bendamustine + rituximab...(not recommended if treated with prior bendamustine)...
    Secondary therapy:
    bendamustine; cyclophosphamide; lenalidomide; chlorambucil